6 results on '"Franke, Molly F."'
Search Results
2. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB.
- Author
-
Khan, Faiz Ahmad, Gelmanova, Irina Y., Franke, Molly F., Atwood, Sidney, Zemlyanaya, Nataliya A., Unakova, Irina A., Andreev, Yevgeniy G., Berezina, Valentina I., Pavlova, Vera E., Shin, Sonya S., Yedilbayev, Askar B., Becerra, Mercedes C., and Keshavjee, Salmaan
- Subjects
MULTIDRUG-resistant tuberculosis ,FLUOROQUINOLONES ,DRUG therapy ,DRUG efficacy ,HEALTH outcome assessment ,THERAPEUTICS - Abstract
Background. We sought to determine whether treatment with a "long aggressive regimen" was associated with lower rates of relapse among patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russia. Methods. We conducted a retrospective cohort study of adult patients that initiated MDR-TB treatment with individualized regimens between September 2000 and November 2004, and were successfully treated. Patients were classified as having received "aggressive regimens" if their intensive phase consisted of at least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for at least 6 months post culture conversion, and their continuation phase included at least 4 likely effective drugs. Patients that were treated with aggressive regimens for a minimum duration of 18 months post culture conversion were classified as having received "long aggressive regimens." We used recurrence as a proxy for relapse because genotyping was not performed. After treatment, patients were classified as having disease recurrence if cultures grew MDR-TB or they re-initiated MDR-TB therapy. Data were analyzed using Cox proportional hazard regression. Results. Of 408 successfully treated patients, 399 (97.5%) with at least 1 follow-up visit were included. Median duration of follow-up was 42.4 months (interquartile range: 20.5-59.5), and there were 27 recurrence episodes. In a multivariable complete case analysis (n = 371 [92.9%]) adjusting for potential confounders, long aggressive regimens were associated with a lower rate of recurrence (adjusted hazard ratio: 0.22, 95% confidence interval, .05-.92). Conclusions. Long aggressive regimens for MDR-TB treatment are associated with lower risk of disease recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and Death.
- Author
-
Velásquez, Gustavo E., Becerra, Mercedes C., Gelmanova, Irina Y., Pasechnikov, Alexander D., Yedilbayev, Askar, Shin, Sonya S., Andreev, Yevgeny G., Yanova, Galina, Atwood, Sidney S., Mitnick, Carole D., Franke, Molly F., Rich, Michael L., and Keshavjee, Salmaan
- Subjects
MULTIDRUG-resistant tuberculosis ,ANTITUBERCULAR agents ,MORTALITY ,MEDICAL statistics ,HEALTH outcome assessment ,PREVENTION - Abstract
In this retrospective cohort study of patients treated for multidrug-resistant tuberculosis in the Russian Federation, we found that monthly exposure to an aggressive multidrug-resistant tuberculosis regimen was a robust predictor of decreased risk of death or failure during treatment.Background. Evidence is sparse regarding the optimal construction of regimens to treat multidrug-resistant (MDR) tuberculosis disease due to strains of Mycobacterium tuberculosis resistant to at least both isoniazid and rifampin. Given the low potency of many second-line antituberculous drugs, we hypothesized that an aggressive regimen of at least 5 likely effective drugs during the intensive phase, including a fluoroquinolone and a parenteral agent, would be associated with a reduced risk of death or treatment failure.Methods. We conducted a retrospective cohort study of patients initiating MDR tuberculosis treatment between 2000 and 2004 in Tomsk, Russian Federation. We used a multivariate Cox proportional hazards model to assess whether monthly exposure to an aggressive regimen was associated with the risk of death or treatment failure.Results. Six hundred fourteen individuals with confirmed MDR tuberculosis were eligible for analysis. On multivariable analysis that adjusted for extensively drug-resistant (XDR) tuberculosis—MDR tuberculosis isolates resistant to fluoroquinolones and parenteral agents—we found that monthly exposure to an aggressive regimen was significantly associated with a lower risk of death or treatment failure (hazard ratio, 0.52 [95% confidence interval, .29–.94]; P = .030).Conclusions. Receipt of an aggressive treatment regimen was a robust predictor of decreased risk of death or failure during MDR tuberculosis treatment. These findings further support the use of this regimen definition as the benchmark for the standard of care of MDR tuberculosis patients and should be used as the basis for evaluating novel therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Implementation of GenoType MTBDRplus Reduces Time to Multidrug-Resistant Tuberculosis Therapy Initiation in South Africa.
- Author
-
Jacobson, Karen R., Theron, Danie, Kendall, Emily A., Franke, Molly F., Barnard, Marinus, van Helden, Paul D., Victor, Tommie C., Streicher, Elizabeth M., Murray, Megan B., and Warren, Robin M.
- Subjects
MULTIDRUG-resistant tuberculosis ,COHORT analysis ,MICROBIAL sensitivity tests ,MULTIVARIATE analysis ,TUBERCULOSIS treatment ,INFECTIOUS disease transmission - Abstract
Introduction of the rapid MTBDRplus diagnostic led to a significant improvement in time to multidrug-resistant tuberculosis treatment initiation. However, delays in laboratory processing, result reporting, and therapy initiation require reduction to have maximum impact on treatment outcomes and transmission interruption.Background. Diagnosis of drug resistance and timely initiation of multidrug-resistant (MDR) tuberculosis therapy are essential to reduce transmission and improve patient outcomes. We sought to determine whether implementation of the rapid MTBDRplus diagnostic shortened the time from specimen collection to patient MDR tuberculosis therapy initiation.Methods. We conducted a retrospective cohort analysis of 197 MDR tuberculosis patients treated at Brewelskloof, a rural tuberculosis hospital in Western Cape Province, South Africa, between 2007 and 2011.Results. Eighty-nine patients (45%) were tested using conventional liquid culture and drug susceptibility testing (DST) on solid medium and 108 (55%) were tested using the MTBDRplus assay after positive acid-fast bacilli or culture. Median time from sample taken to therapy initiation was reduced from 80 days (interquartile range [IQR] 62–100) for conventional DST to 55 days (IQR 37.5–78) with the MTBDRplus. Although the laboratory processing time declined significantly, operational delays persisted both in the laboratory and the clinical infrastructure for getting patients started on treatment. In multivariate analysis, patients tested using the MTBDRplus test had a reduced risk of starting treatment 60 days or more after sputum collection of 0.52 (P < .0001) compared with patients tested with culture-based DST, after adjustment for smear status and site of disease.Conclusions. Use of MTBDRplus significantly reduced time to MDR tuberculosis treatment initiation. However, DST reporting to clinics was delayed by more than 1 week due, in part, to laboratory operational delays, including dependence on smear and culture positivity prior to MTBDRplus performance. In addition, once MDR tuberculosis was reported, delays in contacting patients and initiating therapy require improvements in clinical infrastructure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Risk Factors and Mortality Associated with Default from Multidrug-Resistant Tuberculosis Treatment.
- Author
-
Franke, Molly F., Appleton, Sasha C., Bayona, Jaime, Arteaga, Fernando, Palacios, Eda, Llaro, Karim, Shin, Sonya S., Becerra, Mercedes C., Murray, Megan B., and Mitnick, Carole D.
- Subjects
- *
MULTIDRUG-resistant tuberculosis , *THERAPEUTICS , *MORTALITY , *DISEASE risk factors , *PATIENTS , *EDUCATIONAL attainment , *DIAGNOSIS , *MYCOBACTERIAL diseases , *SPUTUM , *TUBERCULOSIS - Abstract
Background. Completing treatment for multidrug-resistant (MDR) tuberculosis (TB) may be more challenging than completing first-line TB therapy, especially in resource-poor settings. The objectives of this study were to (1) identify risk factors for default from MDR TB therapy (defined as prolonged treatment interruption), (2) quantify mortality among patients who default from treatment, and (3) identify risk factors for death after default from treatment. Methods. We performed a retrospective chart review to identify risk factors for default from MDR TB therapy and conducted home visits to assess mortality among patients who defaulted from such therapy. Results. Sixty-seven (10.0%) of 671 patients defaulted from MDR TB therapy. The median time to treatment default was 438 days (interquartile range, 152–710 days), and 27 (40.3%) of the 67 patients who defaulted from treatment had culture-positive sputum at the time of default. Substance use (hazard ratio, 2.96; 95% confidence interval, 1.56–5.62; P =.001), substandard housing conditions (hazard ratio, 1.83; 95% confidence interval, 1.07-3.11; P =.03), later year of enrollment (hazard ratio, 1.62, 95% confidence interval, 1.09–2.41; P =.02), and health district (P =.02) predicted default from therapy in a multivariable analysis. Severe adverse events did not predict default from therapy. Forty-seven (70.1%) of 67 patients who defaulted from therapy were successfully traced; of these, 25 (53.2%) had died. Poor bacteriologic response, <1 year of treatment at the time of default, low education level, and diagnosis with a psychiatric disorder significantly predicted death after default in a multivariable analysis. Conclusions. The proportion of patients who defaulted from MDR TB treatment was relatively low. The large proportion of patients who had culture-positive sputum at the time of treatment default underscores the public health importance of minimizing treatment default. Prognosis for patients who defaulted from therapy was poor. Interventions aimed at preventing treatment default may reduce TB-related mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Recurrence after Treatment for Pulmonary Multidrug-Resistant Tuberculosis.
- Author
-
Becerra, Mercedes C., Appleton, Sasha C., Franke, Molly F., Chalco, Katiuska, Bayona, Jaime, Murray, Megan B., and Mitnick, Carole D.
- Subjects
DISEASE relapse ,MULTIDRUG-resistant tuberculosis ,TUBERCULOSIS treatment ,TREATMENT effectiveness ,DRUG resistance in microorganisms ,MYCOBACTERIAL disease treatment ,LUNG diseases ,DRUG efficacy - Abstract
We estimated the proportion of recurrence within 2 years among adults cured by individualized multidrug-resistant tuberculosis regimens in Peru. Among 310 individuals with at least 24 months of follow-up, 16 experienced an episode of recurrent tuberculosis. If we assume the worst for treatment effectiveness—that all 16 episodes were caused by the original tuberculosis strain—then 5.2% (95% confidence interval, 3.0%-8.2%) experienced true relapse. This is an upper-bound estimate of relapse on which new regimens must improve. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.